Navigation Links
Genova files patent for new prostate cancer treatment
Date:9/8/2009

NEW YORK, Sept. 8 /PRNewswire-FirstCall/ - (OTCBB: GVBP.OB) - GENova Biotherapeutics, Inc., ("GENova"), is pleased to announce that it has filed a patent for a novel peptide that disrupts the advance of prostate cancer and thus has blockbuster potential as a new anti-cancer drug.

The peptide, called Prostaganin, is a 21-amino compound which is highly reactive to prostate cancer cells, and has the ability to specifically target them. In laboratory experiments, Prostaganin has demonstrated an ability to preferentially bind to and disrupt certain negatively charged components of the membranes of prostate cancer cells.

Prostaganin thus has tremendous potential as a superior new form of treating prostate cancer. Current treatment methods such as surgery, radiation and chemotherapy are outmoded, unsatisfactory, and have severe side effects. Prostaganin offers a positive alternative. The peptide, bio-engineered from naturally occurring compounds in the human body, can target and destroy cancerous cells, whilst leaving surrounding healthy tissues intact, and causing no undesirable side effects. Further development of this novel peptide could revolutionize the way people fight cancer.

The demand for new and better treatments for prostate cancer has never been higher. Prostate cancer presently accounts for 30% of all the major cancers in men. The Prostate Cancer Foundation states that prostate cancer is the cancer with the largest expected increase in the next decade, and that annual incidence of the cancer will rise to 300,000 cases in the U.S. alone by 2015.

"Prostaginin represents a significant milestone in GENova's business agenda to acquire patents for the most innovative new cancer treatments," says Aaron Whiteman, CEO of GENova, "But most importantly, it represents a new generation of cancer treatments that could save millions of lives, and treat prostate cancer in men with no side effects or adverse effects on quality of life. Th
'/>"/>

SOURCE GENova Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. GENova names Dr. John Savin as Vice President
2. GENova names Aaron Whiteman as CEO
3. Sun Pharmaceutical Files HSR Application for Taro Tender Offer
4. InfoLogix Files Preliminary Proxy Statement in Connection with Special Meeting of Its Stockholders to Approve Recapitalization Plan
5. VirtualHealth Technologies Files 8k Related to the August 17th Announcement of Private Access Payment and Document Modification
6. Profiles International Releases New Study Identifying Key Factors for Strategic Workforce Planning
7. "Med Records to Go" Stores Document and Image Files of Medical Facilities for Emergency Viewing
8. AMDL Inc. Files Notification of Late Filing for Form 10-Q
9. Texas Law Firm Files Multiple Suits Against Medtronic as Deadline Approaches
10. Star Scientific Files Second Quarter Financial Results; Rock Creek Pharmaceuticals Reports Early Promising Results in Studies Assessing Safety and Viability of Active Components for a Non-Nicotine Nutraceutical (CigRx(TM))
11. Vitamin Shoppe Files Registration Statement for Initial Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... (PRWEB) April 20, 2015 Mutare ... has secured nationally-renowned Gastroenterologist Lawrence Kosinski, MD, MBA, ... , Dr. Kosinski brings a unique combination of ... to the Mutare Health team as ... communication, collaboration, and quality of care in the ...
(Date:4/20/2015)... Danbury, Connecticut (PRWEB) April 20, 2015 ... that Moreen Donahue, DNP, RN, NEA-BC, FAAN who ... for Nursing Education and Research in September 2014, ... Chief Nursing Officer to lead the development of ... In this newly created role, Donahue will be ...
(Date:4/20/2015)... April 20, 2015 Novatus, a ... further expanded its service level to the growing ... in Amsterdam and Paris. After a rigorous ... sophisticated levels of resilience, security and operational expertise, ... milestone for Novatus as we expand our footprint ...
(Date:4/20/2015)... Southfield, MI (PRWEB) April 20, 2015 ... products is a personal matter that many customers would prefer ... offering as of March 30th a discreet delivery method allowing ... have them arrive at their home without fear of a ... This discreet shipping method is available now on all orders ...
(Date:4/20/2015)... (PRWEB) April 20, 2015 America’s ... the U.S. health insurance industry, is seeking greater ... the recent controversy involving surgical tools called power ... U.S. Senator Robert Casey (D-PA) dated April 14th, ... uterine morcellation point to “serious gaps in the ...
Breaking Medicine News(10 mins):Health News:Dr. Lawrence Kosinski Merges Medical, Technical, Business Expertise as CMO for Mutare Health 2Health News:Dr. Lawrence Kosinski Merges Medical, Technical, Business Expertise as CMO for Mutare Health 3Health News:Nursing Executive to Develop and Lead Nursing Leadership Program at Western Connecticut Health Network 2Health News:Novatus Expands into European Data Centers 2Health News:Advance Home Care Supply Proud to Offer Discreet Delivery For All Orders 2Health News:Advance Home Care Supply Proud to Offer Discreet Delivery For All Orders 3Health News:Power Morcellator Lawyers at Bernstein Liebhard LLP Comment on Insurance Trade Group’s Call for Greater Regulation of Medical Devices 2Health News:Power Morcellator Lawyers at Bernstein Liebhard LLP Comment on Insurance Trade Group’s Call for Greater Regulation of Medical Devices 3Health News:Power Morcellator Lawyers at Bernstein Liebhard LLP Comment on Insurance Trade Group’s Call for Greater Regulation of Medical Devices 4
... years,since the nation,s capital was stunned by terrorist ... are we any better prepared now than we,were ... Hospital,Center will answer the question, Tuesday evening, October ... READY?" -- as they present the,Washington Hospital Center,s ...
... Renowned Therapist Challenges Modern Psychology and Explodes Myths of ,Why ... ... children have a,genetic predisposition to bad behavior and are more difficult to ... parents, has,been the cross parents have had to bear for decades, placing ...
... October 29, 2007 - A new study published in ... self-reported active epilepsy and health-related quality of life among ... data collected in the 2003 California Health Interview Survey ... finds that in 2003, almost 300,000 (1.2 percent) adults ...
... - Monthly blog will appear in conjunction with ... 29 The Kellogg School,of Management at Northwestern ... monthly blog developed by David Dranove, the Kellogg ... Management.,"Code Red" is accessible at the following link:, ...
... (Amex: PRZ ), one of the nation,s leading ... announced that at its,2007 Annual Meeting of Stockholders held ... of board members and the,ratification of Brimmer, Burek & ... ending December 31, 2007. Re-elected board members, who ...
... Pharmaceuticals,Inc., which discovers and develops novel antiviral therapeutics ... of Steven D.,Skolsky as its President and Chief ... of the Board of Directors. "Sequoia is ... as Steven Skolsky," said Chris Mirabelli, Chairman of ...
Cached Medicine News:Health News:Are We Ready? Washington Hospital Center Sets Precedents in Preparedness for 9/11-Style Attacks 2Health News:Bad Children Can Happen to Good Parents: A Survival Manual for Parents of Difficult Children by Norman E. Hoffman, Ph.D. 2Health News:Bad Children Can Happen to Good Parents: A Survival Manual for Parents of Difficult Children by Norman E. Hoffman, Ph.D. 3Health News:Kellogg School of Management Announces 'Code Red' 2Health News:PainCare Announces Results of 2007 Annual Meeting of Stockholders 2Health News:PainCare Announces Results of 2007 Annual Meeting of Stockholders 3Health News:Sequoia Pharmaceuticals Announces Appointment of Steven D. Skolsky as Chief Executive Officer 2
(Date:4/20/2015)... 20, 2015 International Isotopes Inc. (OTCQB: ... shareholders with the following update on its business ... Historically, INIS has produced and sold ... models of sealed sources for medical and industrial ... therapy, security examination, and radiography.  Due to technical ...
(Date:4/20/2015)... KANNAPOLIS, N.C. , April 20, 2015 /PRNewswire/ ... managed care organization that focuses on high-tech, high-touch ... for delivering behavioral health services during the National ... The event, which takes place April 20–22, 2015, ... in Orlando, Fla. , attracts ...
(Date:4/20/2015)... , April 20, 2015 Eli Lilly ... the investigational medicine ixekizumab was statistically superior to placebo ... (PsA), as demonstrated by the proportion of patients achieving ... assessment that represents a 20 percent reduction in disease ... of Rheumatology response criteria. During the 24-week, Phase 3 ...
Breaking Medicine Technology:International Isotopes Inc. Provides Shareholders With An Update On New Opportunities And Positive Developments Within Its Existing Business Segments 2International Isotopes Inc. Provides Shareholders With An Update On New Opportunities And Positive Developments Within Its Existing Business Segments 3International Isotopes Inc. Provides Shareholders With An Update On New Opportunities And Positive Developments Within Its Existing Business Segments 4International Isotopes Inc. Provides Shareholders With An Update On New Opportunities And Positive Developments Within Its Existing Business Segments 5Cardinal Innovations Highlights its Managed Care Model During National Council for Behavioral Health's Annual Conference 2Cardinal Innovations Highlights its Managed Care Model During National Council for Behavioral Health's Annual Conference 3Lilly's Ixekizumab Met Primary Endpoint in a Phase 3 Study Investigating the Treatment of Psoriatic Arthritis 2Lilly's Ixekizumab Met Primary Endpoint in a Phase 3 Study Investigating the Treatment of Psoriatic Arthritis 3Lilly's Ixekizumab Met Primary Endpoint in a Phase 3 Study Investigating the Treatment of Psoriatic Arthritis 4
... LAUSANNE, Switzerland, July 21 Debiopharm Group,(Debiopharm), ... focus on the development of prescription drugs that ... agency for therapeutic products,Swissmedic, has issued a marketing ... prescribed for a reversible reduction,of serum testosterone to ...
... Ueno, Ltd. announced on July 17 that as a phase 1 ... by our company as a therapeutic drug of androgenetic alopecia (male ... , The phase 1 clinical study of ... study and 5-day repeated-dose study. Since no serious adverse event occurred ...
Cached Medicine Technology:Swissmedic Grants Debiopharm Marketing Authorisation for Moapar(R), a New Therapeutic Avenue for the Treatment of Sexual Deviations 2Swissmedic Grants Debiopharm Marketing Authorisation for Moapar(R), a New Therapeutic Avenue for the Treatment of Sexual Deviations 3R-Tech Ueno, Ltd. Completes Phase 1 Clinical Study on RK-023 2R-Tech Ueno, Ltd. Completes Phase 1 Clinical Study on RK-023 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: